

Bruce R Schackman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2937151/publications.pdf>

Version: 2024-02-01

185
papers

7,747
citations

61984

43
h-index

60623

81
g-index

189
all docs

189
docs citations

189
times ranked

7783
citing authors

#	ARTICLE	IF	CITATIONS
1	Costs of Opioid Overdose Education and Naloxone Distribution in New York City. <i>Substance Abuse</i> , 2022, 43, 692-698.	2.3	5
2	Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	3.3	8
3	Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109323.	3.2	20
4	Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109265.	3.2	1
5	The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice. <i>Substance Use and Misuse</i> , 2022, 57, 308-315.	1.4	0
6	Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City. <i>Journal of Urban Health</i> , 2021, 98, 563-569.	3.6	5
7	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021, 88, 102726.	3.3	5
8	The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2021, 72, e828-e834.	5.8	30
9	A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study. <i>Journal of General Internal Medicine</i> , 2021, 36, 1898-1905.	2.6	21
10	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
11	Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder research. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 32.	2.2	1
12	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. <i>Addiction</i> , 2021, 116, 3444-3453.	3.3	1
13	Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. <i>Medical Care</i> , 2021, 59, 795-800.	2.4	1
14	Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review. <i>Value in Health</i> , 2021, 24, 1068-1083.	0.3	17
15	Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. <i>Lancet HIV</i> , 2021, 8, e581-e590.	4.7	9
16	Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use. <i>American Journal of Preventive Medicine</i> , 2021, 61, 537-544.	3.0	5
17	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	3.3	13
18	Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	2.1	2

#	ARTICLE	IF	CITATIONS
19	Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study. <i>Journal of Public Health Management and Practice</i> , 2021, 27, 393-402.	1.4	7
20	Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1397-1405.	5.8	13
21	Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 975-977.	2.6	3
22	Spatial distribution and characteristics of HIV clusters in Ethiopia. <i>Tropical Medicine and International Health</i> , 2020, 25, 301-307.	2.3	9
23	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <i>Aids</i> , 2020, 34, 447-458.	2.2	36
24	Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results. <i>Medical Care</i> , 2020, 58, 445-452.	2.4	9
25	State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events. <i>Medical Care</i> , 2020, 58, 610-616.	2.4	8
26	Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. <i>Journal of Infectious Diseases</i> , 2020, 222, S322-S334.	4.0	10
27	Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108221.	3.2	11
28	Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. <i>Medical Decision Making</i> , 2020, 40, 718-721.	2.4	4
29	The Value and Challenge of Frequent Human Immunodeficiency Virus (HIV) Testing Among Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2020, 73, e1936-e1937.	5.8	1
30	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108336.	3.2	8
31	Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program. <i>Journal of Infectious Diseases</i> , 2020, 222, S335-S345.	4.0	8
32	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <i>Journal of Infectious Diseases</i> , 2020, 222, S301-S311.	4.0	4
33	COVID-19 Could Change the Way We Respond to the Opioid Crisisâ€”for the Better. <i>Psychiatric Services</i> , 2020, 71, 1214-1215.	2.0	19
34	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2307-2315.	2.4	2
35	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.2	50
36	Ending the HIV epidemic in the USA: an economic modelling study in six cities. <i>Lancet HIV</i> , 2020, 7, e491-e503.	4.7	44

#	ARTICLE	IF	CITATIONS
37	Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. <i>Medical Decision Making</i> , 2020, 40, 3-16.	2.4	25
38	Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 18-27.	2.8	7
39	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	5.9	17
40	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.	3.1	6
41	“Ending the Epidemic” Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic. <i>Clinical Infectious Diseases</i> , 2020, 71, 2968-2971.	5.8	25
42	Can the “Ending the HIV Epidemic”™ initiative transition the USA towards HIV/AIDS epidemic control?. <i>Aids</i> , 2020, 34, 2325-2328.	2.2	4
43	Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. <i>Journal of Substance Abuse Treatment</i> , 2019, 106, 79-88.	2.8	17
44	Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?. <i>Journal of Substance Abuse Treatment</i> , 2019, 105, 37-43.	2.8	31
45	Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial. <i>Implementation Science</i> , 2019, 14, 62.	6.9	6
46	Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2019, 69, 2195-2198.	5.8	20
47	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019, 37, 1219-1239.	3.3	7
48	Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. <i>PLoS ONE</i> , 2019, 14, e0217559.	2.5	31
49	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. <i>International Journal of Drug Policy</i> , 2019, 72, 160-168.	3.3	23
50	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	3.2	113
51	Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. <i>Journal of Public Health Management and Practice</i> , 2019, 25, 245-252.	1.4	15
52	Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821882196.	1.5	6
53	Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 5.	2.6	28
54	Will converting naloxone to over-the-counter status increase pharmacy sales?. <i>Health Services Research</i> , 2019, 54, 764-772.	2.0	25

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz537.	0.9	6
56	Cost of an HIV Medical Care Coordination Program in Los Angeles County. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e15-e17.	2.1	2
57	A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination. <i>Journal of Public Health Management and Practice</i> , 2019, 25, 253-261.	1.4	7
58	Commentary on Barbosa et al. (2019): The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs. <i>Addiction</i> , 2019, 114, 2279-2280.	3.3	0
59	Cost-Effectiveness of Buprenorphine+Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. <i>Annals of Internal Medicine</i> , 2019, 170, 90.	3.9	50
60	Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. <i>Drug and Alcohol Dependence</i> , 2018, 185, 411-420.	3.2	22
61	Treating and Preventing HIV with Generic Drugs – Barriers in the United States. <i>New England Journal of Medicine</i> , 2018, 378, 316-319.	27.0	10
62	State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1618-1620.	5.8	22
63	Implementation of a Nationwide Health Economic Consultation Service to Assist Substance use Researchers: Lessons Learned. <i>Substance Abuse</i> , 2018, 39, 185-189.	2.3	4
64	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 90-96.	2.8	233
65	Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. <i>Clinical Infectious Diseases</i> , 2018, 66, 376-384.	5.8	62
66	2216. Hepatitis C Treatment Wanted Yet Not Received: Barriers to Receiving HCV Treatment Among People Who Inject Drugs. <i>Open Forum Infectious Diseases</i> , 2018, 5, S654-S655.	0.9	1
67	862. Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters. <i>Open Forum Infectious Diseases</i> , 2018, 5, S21-S21.	0.9	0
68	Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e76-e78.	2.1	21
69	No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. <i>PLoS ONE</i> , 2018, 13, e0206577.	2.5	3
70	Criminal justice measures for economic data harmonization in substance use disorder research. <i>Health and Justice</i> , 2018, 6, 17.	2.1	5
71	Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions. <i>Health Affairs</i> , 2018, 37, 1596-1604.	5.2	67
72	First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults. <i>Journal of General Internal Medicine</i> , 2018, 33, 2156-2162.	2.6	18

#	ARTICLE	IF	CITATIONS
73	The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1030-1035.	1.3	19
74	Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. <i>BMC Infectious Diseases</i> , 2018, 18, 74.	2.9	23
75	Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE. <i>Learning Health Systems</i> , 2018, 2, e10056.	2.0	9
76	Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. <i>American Journal of Managed Care</i> , 2018, 24, 526-531.	1.1	9
77	Joint Utility Estimators in Substance Use Disorders. <i>Value in Health</i> , 2017, 20, 458-465.	0.3	14
78	Quality of life as an outcome of opioid use disorder treatment: A systematic review. <i>Journal of Substance Abuse Treatment</i> , 2017, 76, 88-93.	2.8	50
79	States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees. <i>Health Affairs</i> , 2017, 36, 733-741.	5.2	102
80	Monetary conversion factors for economic evaluations of substance use disorders. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 25-34.	2.8	36
81	When "the Cure" Is the Risk: Understanding How Substance Use Affects HIV and HCV in a Layered Risk Environment in San Juan, Puerto Rico. <i>Health Education and Behavior</i> , 2017, 44, 748-757.	2.5	5
82	The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto Rico. <i>BMC Health Services Research</i> , 2017, 17, 232.	2.2	3
83	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.9	14
84	Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 146-154.	2.1	8
85	Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. <i>Addiction</i> , 2016, 111, 675-684.	3.3	29
86	Costs of Expanded Rapid HIV Testing in Four Emergency Departments. <i>Public Health Reports</i> , 2016, 131, 71-81.	2.5	19
87	Substance use and STI acquisition: Secondary analysis from the AWARE study. <i>Drug and Alcohol Dependence</i> , 2016, 169, 171-179.	3.2	18
88	Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. <i>Health Affairs</i> , 2016, 35, 1045-1051.	5.2	273
89	On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial. <i>Trials</i> , 2016, 17, 117.	1.6	12
90	Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. <i>PLoS ONE</i> , 2016, 11, e0148106.	2.5	11

#	ARTICLE	IF	CITATIONS
91	Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. <i>HIV Clinical Trials</i> , 2015, 16, 207-218.	2.0	4
92	Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 304-310.	2.1	15
93	Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. <i>Addiction</i> , 2015, 110, 129-143.	3.3	39
94	Performance of a Mathematical Model to Forecast Lives Saved from HIV Treatment Expansion in Resource-Limited Settings. <i>Medical Decision Making</i> , 2015, 35, 230-242.	2.4	4
95	Carotid Artery Stenosis: Cost-effectiveness of Assessment of Cerebrovascular Reserve to Guide Treatment of Asymptomatic Patients. <i>Radiology</i> , 2015, 274, 455-463.	7.3	12
96	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1102-1110.	5.8	41
97	An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. <i>International Journal of Drug Policy</i> , 2015, 26, 1056-1063.	3.3	33
98	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. <i>Annals of Internal Medicine</i> , 2015, 162, 619-629.	3.9	92
99	The Lifetime Medical Cost Savings From Preventing HIV in the United States. <i>Medical Care</i> , 2015, 53, 293-301.	2.4	94
100	Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. <i>Pharmacogenomics</i> , 2015, 16, 2007-2018.	1.3	19
101	The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes. <i>PLoS ONE</i> , 2014, 9, e97317.	2.5	109
102	The Cost of Implementing Rapid HIV Testing in Sexually Transmitted Disease Clinics in the United States. <i>Sexually Transmitted Diseases</i> , 2014, 41, 545-550.	1.7	20
103	The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2014, 28, 365-376.	2.2	20
104	Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. <i>Transfusion</i> , 2014, 54, 889-899.	1.6	36
105	Health-Related Quality of Life in HIV-Infected and At-Risk Women. <i>Medical Decision Making</i> , 2014, 34, 800-808.	2.4	13
106	Cost-Effectiveness Analysis of Ugt1A1 Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease. <i>Antiviral Therapy</i> , 2013, 18, 399-408.	1.0	11
107	Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1701.	7.4	111
108	The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 90-97.	3.2	32

#	ARTICLE	IF	CITATIONS
109	Updating the HIV-Testing Guidelines â€” A Modest Change with Major Consequences. <i>New England Journal of Medicine</i> , 2013, 368, 884-886.	27.0	22
110	AIDS Drug Assistance Programs: Managers Confront Uncertainty And Need To Adapt As The Affordable Care Act Kicks In. <i>Health Affairs</i> , 2013, 32, 1063-1071.	5.2	12
111	A Call For Evidence-Based Medical Treatment Of Opioid Dependence In The United States And Canada. <i>Health Affairs</i> , 2013, 32, 1462-1469.	5.2	114
112	Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1607-1617.	5.8	40
113	The State(s) of Health: Federalism and the Implementation of Health Reform in the Context of <scp>HIV</scp> Care. <i>Public Administration Review</i> , 2013, 73, S94.	4.1	3
114	The Value of HIV Screening in the United States in the Era of Effective Treatment. <i>Medical Decision Making</i> , 2013, 33, 457-459.	2.4	2
115	Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States. <i>Annals of Internal Medicine</i> , 2013, 158, 84.	3.9	117
116	Lives Saved by Expanding HIV Treatment Availability in Resource-Limited Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e40-e48.	2.1	9
117	Cost-Effectiveness of Generic Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 776.	3.9	5
118	Considerations for Developing Applied Health Policy Models: The Example of HIV Treatment Expansion in Resource-Limited Settings. <i>Profiles in Operations Research</i> , 2013, , 313-339.	0.4	2
119	Costâ€”effectiveness of pre-exposure prophylaxis for HIV. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 587-592.	3.8	51
120	Cost-effective Screening for Acute Hepatitis C Virus Infection in HIV-Infected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2012, 55, 279-290.	5.8	54
121	Appropriateness Criteria and Elective Procedures â€” Total Joint Arthroplasty. <i>New England Journal of Medicine</i> , 2012, 367, 2467-2469.	27.0	70
122	Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. <i>American Journal of Public Health</i> , 2012, 102, 1160-1167.	2.7	86
123	Newer drugs and earlier treatment. <i>Aids</i> , 2012, 26, 45-56.	2.2	74
124	What Does US Health Reform Mean for HIV Clinical Care?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 72-76.	2.1	27
125	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	8
126	Inappropriate Medication in a National Sample of US Elderly Patients Receiving Home Health Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 304-310.	2.6	67

#	ARTICLE	IF	CITATIONS
127	Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 669-676.	2.6	81
128	Inappropriate Medication in Home Health Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 491-491.	2.6	4
129	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	4
130	NIDA's Clinical Trials Network: An Opportunity for HIV Research in Community Substance Abuse Treatment Programs. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 283-293.	2.1	5
131	The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S76-S82.	2.1	18
132	Collaborative Depression Care Management and Disparities in Depression Treatment and Outcomes. <i>Archives of General Psychiatry</i> , 2011, 68, 627.	12.3	52
133	Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. <i>PLoS Medicine</i> , 2011, 8, e1001095.	8.4	29
134	Results From a New York City Emergency Department Rapid HIV Testing Program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 420-422.	2.1	20
135	Implementation Science for the Prevention and Treatment of HIV/AIDS. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, S27-S31.	2.1	71
136	Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. <i>Value in Health</i> , 2010, 13, 893-902.	0.3	23
137	Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure. <i>Journal of Infectious Diseases</i> , 2010, 201, 100126095936095-000.	4.0	155
138	Clinical Impact and Cost of Monitoring for Asymptomatic Laboratory Abnormalities among Patients Receiving Antiretroviral Therapy in a Resource-Poor Setting. <i>Clinical Infectious Diseases</i> , 2010, 51, 600-608.	5.8	30
139	Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. <i>HIV Clinical Trials</i> , 2010, 11, 248-259.	2.0	17
140	Cost-Effectiveness of Tenofovir as First-Line Antiretroviral Therapy in India. <i>Clinical Infectious Diseases</i> , 2010, 50, 416-425.	5.8	54
141	An In-Depth Survey of the Screening and Assessment Practices of Highly Regarded Adolescent Substance Abuse Treatment Programs. <i>Journal of Child and Adolescent Substance Abuse</i> , 2009, 19, 33-47.	0.5	9
142	Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 992-999.	1.2	18
143	HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. <i>Clinical Infectious Diseases</i> , 2009, 48, 806-815.	5.8	240
144	Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. <i>Cancer</i> , 2009, 115, 3858-3867.	4.1	78

#	ARTICLE	IF	CITATIONS
145	Achieving Effective Antidepressant Pharmacotherapy in Primary Care: The Role of Depression Care Management in Treating Late-Life Depression. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 895-900.	2.6	16
146	Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2009, 49, 1570-1578.	5.8	167
147	The cost of antiretroviral therapy in Haiti. <i>Cost Effectiveness and Resource Allocation</i> , 2008, 6, 3.	1.5	25
148	Can urban methadone patients complete health utility assessments?. <i>Patient Education and Counseling</i> , 2008, 71, 302-307.	2.2	1
149	Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2008, 197, 867-870.	4.0	170
150	Sexually Active HIV-Positive Patients Frequently Report Never Using Condoms in Audio Computer-Assisted Self-Interviews Conducted at Routine Clinical Visits. <i>AIDS Patient Care and STDs</i> , 2008, 22, 123-129.	2.5	16
151	Efavirenz-Based Regimens in Treatment-Naive Patients with a Range of Pretreatment HIV-1 RNA Levels and CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2008, 197, 1006-1010.	4.0	15
152	Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree?. <i>Medical Decision Making</i> , 2008, 28, 233-242.	2.4	32
153	The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. <i>Aids</i> , 2008, 22, 2025-2033.	2.2	130
154	Cost-Effectiveness of Rapid Syphilis Screening in Prenatal HIV Testing Programs in Haiti. <i>PLoS Medicine</i> , 2007, 4, e183.	8.4	58
155	Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 547-554.	2.1	58
156	Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial. <i>Clinical Infectious Diseases</i> , 2007, 45, 1062-1070.	5.8	28
157	Preventing Vertical Hepatitis C Virus Transmission. <i>Clinical Infectious Diseases</i> , 2007, 45, 802-802.	5.8	0
158	Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. <i>Aids</i> , 2007, 21, 813-823.	2.2	22
159	Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programs. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2007, 2, 23.	2.2	7
160	RESPONSE LETTER TO DR. DRINKA. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 960-960.	2.6	0
161	Offers of Hepatitis C Care Do Not Lead to Treatment. <i>Journal of Urban Health</i> , 2007, 84, 455-458.	3.6	22
162	Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. <i>Annals of Internal Medicine</i> , 2006, 145, 797.	3.9	183

#	ARTICLE	IF	CITATIONS
163	The Use of an Educational Video During Informed Consent in an HIV Clinical Trial in Haiti. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 588-591.	2.1	44
164	The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States. <i>Medical Care</i> , 2006, 44, 990-997.	2.4	388
165	Can Hip Protector Use Cost-Effectively Prevent Fractures in Community-Dwelling Geriatric Populations?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1658-1665.	2.6	29
166	RESPONSE TO COMMENTARY BY DR. OLIVER AND COLLEAGUES ON HIP PROTECTORS. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1159-1160.	2.6	0
167	Variations in Self-Rated Health Among Patients with HIV Infection. <i>Quality of Life Research</i> , 2006, 15, 503-514.	3.1	18
168	Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 43, S113-S118.	2.1	46
169	Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection<sub><subTITLE></subTITLE></sub>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 769.	7.4	209
170	Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop. <i>Clinical Infectious Diseases</i> , 2006, 43, S254-S257.	5.8	19
171	The Survival Benefits of AIDS Treatment in the United States. <i>Journal of Infectious Diseases</i> , 2006, 194, 11-19.	4.0	576
172	Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. <i>Antiviral Therapy</i> , 2006, 11, 751-760.	1.0	13
173	A Cost-Benefit Analysis of External Hip Protectors in the Nursing Home Setting. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 190-197.	2.6	36
174	Variation in Orthopaedic Surgeons's Perceptions About the Indications for Rotator Cuff Surgery. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 1978-1984.	3.0	114
175	A synthesis of cost-utility analysis literature in infectious disease. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 383-391.	9.1	15
176	The cost of HIV medication adherence support interventions: Results of a cross-site evaluation. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2005, 17, 927-937.	1.2	16
177	Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. <i>Health Care Financing Review</i> , 2005, 26, 67-80.	1.8	3
178	The Quality of Highly Regarded Adolescent Substance Abuse Treatment Programs. <i>JAMA Pediatrics</i> , 2004, 158, 904.	3.0	117
179	The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. <i>Aids</i> , 2004, 18, 1827-1834.	2.2	19
180	Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2004, 350, 1850-1861.	27.0	495

#	ARTICLE	IF	CITATIONS
181	How Often Do Sensitivity Analyses for Economic Parameters Change Cost-Utility Analysis Conclusions?. <i>Pharmacoeconomics</i> , 2004, 22, 293-300.	3.3	25
182	Letter to the Editor. <i>Medical Decision Making</i> , 2003, 23, 542-543.	2.4	0
183	Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS. <i>Medical Decision Making</i> , 2002, 22, 27-38.	2.4	100
184	Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults. <i>Archives of Internal Medicine</i> , 2002, 162, 2478.	3.8	65
185	Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults. <i>American Journal of Public Health</i> , 2001, 91, 1456-1463.	2.7	46